Ali Zamat

Ali Zamat

Auto-generated profile, based on publicly available information

Ali Zamat

Wallace H. Coulter Department of Biomedical Engineering, Georgia Tech College of Engineering and Emory School of Medicine, Atlanta, GA 30332, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2022 in Science Advances
Verified
Journal Article
Open access
FSFang-Yi Su
Fang-Yi Su
QZQingyang Henry Zhao
Qingyang Henry Zhao
SDShreyas N. Dahotre
Shreyas N. Dahotre
LGLena Gamboa
Lena Gamboa
SBSwapnil Bawage
Swapnil Bawage
GKGabriel A. Kwong
Gabriel A. Kwong
Simultaneous delivery of mRNA to multiple populations of antigen (Ag)–specific CD8 + T cells is challenging given the diversity of peptide epitopes and polymorphism of class I major histocompatibility complexes (MHCI). We developed Ag-presenting nanoparticles (APNs) for mRNA delivery using pMHCI molecules that were refolded with photocleavable peptides to allow rapid ligand exchange by UV light and site-specifically conjugated with a lipid tail for postinsertion into preformed mRNA lipid nanoparticles. Across different TCR transgenic mouse models (P14, OT-1, and Pmel), UV-exchanged APNs bound and transfected their cognate Ag-specific CD8 + T cells equivalent to APNs produced using conventionally refolded pMHCI molecules. In mice infected with PR8 influenza, multiplexed delivery of UV-exchanged APNs against three immunodominant epitopes led to ~50% transfection of a VHH mRNA reporter in cognate Ag-specific CD8 + T cells. Our data show that UV-mediated peptide exchange can be used to rapidly produce APNs for mRNA delivery to multiple populations of Ag-specific T cells in vivo.

12 December 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
LGLena Gamboa
Lena Gamboa
AZAli H. Zamat
Ali H. Zamat
DVDaryll Vanover
Daryll Vanover
CTChloé A. Thiveaud
Chloé A. Thiveaud
HPHannah E. Peck
Hannah E. Peck
GKGabriel A. Kwong
Gabriel A. Kwong
CAR T cell immunotherapy relies on CAR targeting of tumor-associated antigens, yet heterogenous antigen expression, interpatient variation, and off-tumor expression by healthy cells remain barriers. Here, we develop synthetic antigens to sensitize solid tumors for recognition and elimination by CAR T cells. Unlike tumor-associated antigens, we design synthetic antigens that are orthogonal to endogenous proteins to eliminate off-tumor targeting and that have a small genetic footprint to facilitate efficient tumor delivery to tumors by viral vectors. Using the RSV-F camelid single-domain antibody (VHH) as a synthetic antigen, we show that adoptive transfer of αVHH CAR T cells to mice bearing VHH expressing tumors reduced tumor burden in multiple syngeneic mouse models of cancer, improved survival, induced epitope spread, and protected against tumor rechallenge. Our work supports in situ delivery of synthetic antigens to treat antigen low or negative tumors with CAR T cells.

26 April 2025 in bioRxiv
Verified
Preprint
Open access
AZAli Zamat
Ali Zamat
CKChulyong Kim
Chulyong Kim
SSShwetha Sridhar
Shwetha Sridhar
SFSydney Fabrega
Sydney Fabrega
RSRiya Sen
Riya Sen
GKGabriel A. Kwong
Gabriel A. Kwong
Achieving durable CAR T cell responses against primary brain tumors and metastases requires strategies that enable intracranial control of therapy to overcome the barriers of solid tumor treatment without compromising safety. Here, we show that closed-loop sonothermogenetics enables remote regulation of CAR T cell therapeutic activity through the intact skull. Using MR-guided focused ultrasound with closed-loop temperature feedback, we modulate CAR T cells engineered with a genetically encoded thermal bioswitch to achieve metronomic activation in the brain without lasting adverse effects on healthy brain tissue. In murine models of brain cancer, metronomic production of NKG2D T cell engagers by intratumoral CAR T cells overcomes antigen heterogeneity in breast cancer brain metastasis and myeloid-derived immunosuppression in glioblastoma to drive antitumor responses. Our findings support the use of closed-loop sonothermogenetics for spatial and temporal control of CAR T cell therapies targeting solid brain tumors.

15 October 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
FSFang-Yi Su
Fang-Yi Su
QZQingyang Zhao
Qingyang Zhao
SDShreyas N. Dahotre
Shreyas N. Dahotre
LGLena Gamboa
Lena Gamboa
SBSwapnil Subhash Bawage
Swapnil Subhash Bawage
GKGabriel A. Kwong
Gabriel A. Kwong
Simultaneous delivery of mRNA to multiple populations of antigen (Ag)-specific CD8 + T cells is challenging given the diversity of peptide epitopes and polymorphism of class I major histocompatibility complexes (MHCI). We developed Ag-presenting nanoparticles (APNs) for mRNA delivery using pMHCI molecules that were refolded with photocleavable peptides to allow rapid ligand exchange by UV light and site-specifically conjugated with a lipid tail for post-insertion into preformed mRNA lipid nanoparticles. Across different TCR transgenic mouse models (P14, OT-1, Pmel), UV-exchanged APNs bound and transfected their cognate Ag-specific CD8 + T cells equivalent to APNs produced using conventionally refolded pMHCI molecules. In mice infected with PR8 influenza, multiplexed delivery of UV-exchanged APNs against three immunodominant epitopes led to ~50% transfection of a VHH mRNA reporter in cognate Ag-specific CD8+ T cells. Our data shows that UV-mediated peptide exchange can be used to rapidly produce APNs for mRNA delivery to multiple populations of Ag-specific T cells in vivo . Teaser: Light-induced rapid production of antigen-presenting nanoparticles for mRNA delivery to multiple virus-specific T cell populations.

20 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
HPHathaichanok Phuengkham
Hathaichanok Phuengkham
YCYing Chen
Ying Chen
ASAnirudh Sivakumar
Anirudh Sivakumar
AZAli H. Zamat
Ali H. Zamat
LGLena Gamboa
Lena Gamboa
GKGabriel A. Kwong
Gabriel A. Kwong
Early cancer detection has the potential to reduce cancer mortality, yet endogenous tumor-shed biomarkers lack sensitivity for early-stage disease. We report OncoSCOUT, a cancer detection strategy using T cells engineered with protease-activatable receptors (PARs) that conditionally recognize tumor cells and release a synthetic biomarker for detection in urine. These PARs comprise masked synthetic Notch receptors in which antigen binding is blocked by a peptide mimotope tethered via a protease-cleavable linker. We demonstrate that requiring both extracellular protease activity and tumor antigen recognition improves spatial specificity and minimizes off-tumor activation of PAR T cells in vivo . To identify tumor-selective PARs, we adoptively transferred a HER2-targeted PAR library displaying ∼160,000 unique 4-mer amino acid linkers and discovered multiple variants significantly enriched in a HER2-positive cancer xenograft model. Using a single customized PAR, we show that OncoSCOUT can detect total tumor burdens as small as 10–30 mm 3 with significantly improved sensitivity than the protein biomarker CA 15-3 or a 20-plex circulating tumor DNA (ctDNA) assay.